Longevity + SkinResearch-onlyEarly humanUpdated 2026-04-22

Peptide reference file

Epithalon

Trending #4 in Longevity21.8k searches/moMixed

Epithalon is discussed as a short synthetic peptide associated with aging biology claims, including telomerase-related narratives.

Current readout: early human evidence, research-only status, not approved approval state, human evidence appears in the current trail, registered trials are linked, and 4 linked sources in the seed trail.

PubChem CID 219042 | 138 PubMed results | 1 trial record | 0 DailyMed labels | 0 Drugs@FDA applications

Epithalon is mostly discussed because it is a recurring longevity peptide in biohacking circles because the story is clean, dramatic, and often overstated.

The public claim is straightforward: People talk about epithalon for longevity, sleep rhythm, telomeres, and anti-aging. Human evidence is limited. Lifespan and anti-aging claims need much more caution.

In plain language, epithalon is a short peptide discussed in aging-biology narratives, especially around telomerase-related claims.

Early humanResearch-only
Telomerase discussionAging biologyPineal peptides

Aliases: Epitalon, Ala-Glu-Asp-Gly | Sequence: AEDG

SpecimenEpithalon specimen
AEDG
Formula
C14H22N4O9
Mass
390.35
Evidence
Early human
Residues
4

Most commonly discussed in relation to Telomerase discussion, Aging biology, Pineal peptides.

What Epithalon is

Epithalon is discussed as a short synthetic peptide associated with aging biology claims, including telomerase-related narratives.

Epithalon is grouped under Longevity + Skin on PeptideFactCheck because it is a recurring longevity peptide in biohacking circles because the story is clean, dramatic, and often overstated.

The useful starting point is to separate the molecule itself from the internet story around it. It has a clean longevity story that is easy to repeat online.

Why people keep looking it up

People talk about epithalon for longevity, sleep rhythm, telomeres, and anti-aging.

Epithalon is a short peptide discussed in aging-biology narratives, especially around telomerase-related claims.

Epithalon tends to stay in the conversation because it touches a familiar public theme: telomerase discussion, aging biology, and pineal peptides. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Human evidence is limited. Lifespan and anti-aging claims need much more caution.

Human evidence is limited and uneven, especially for broad lifespan or anti-aging claims.

Preclinical and mechanistic claims have driven much of the interest.

Why this page carries the current tier: Limited human evidence plus heavy online extrapolation.

The current seed trail for Epithalon is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.

Safety, limits, and regulatory context

The main risk is fake certainty: aging endpoints are hard, long-term data is limited, and products vary.

No FDA-approved epithalon drug product is listed in this V1 source trail.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Epithalon. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for Epithalon is CID 219042. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
219042
Formula
C14H22N4O9
Molecular weight
390.35
InChIKey
HGHOBRRUMWJWCU-FXQIFTODSA-N

Matched synonyms include Epitalon, 307297-39-8, Epithalon, Epithalone, Ala-Glu-Asp-Gly, AE-0 peptide, Glycine, L-alanyl-L-alpha-glutamyl-L-alpha-aspartyl-, O65P17785G.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for Epithalon returns 1 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for Epithalon returns 138 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.